InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,426.40
(
0.12%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.77
(
-0.02%
)
Bitcoin
65,461.10
(
0.49%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: oc631 post# 156451

Tuesday, 02/05/2013 12:25:30 AM

Tuesday, February 05, 2013 12:25:30 AM

Post# of 252254
One more thought on the GILD C.C.



The suggestion that longer 24-week dosing might improve Sofo/Riba GT3 SVR rates is non-sense. The difference between interferon-based and oral therapy is becoming quite clear. Whereas 24-weeks of interferon-based dosing brought exceedingly higher SVR rates this is not the case going beyond 12-weeks of oral treatment.


This is nothing more than false hope being fed to analysts.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up